Literature DB >> 25250942

Type 2 diabetes: a risk factor for liver mortality and complications in hepatitis B cirrhosis patients.

John C Hsiang1, Edward J Gane, Wayne W Bai, Stephen J Gerred.   

Abstract

BACKGROUND AND AIM: The effect of type 2 diabetes mellitus (DM) on morbidity and mortality among hepatitis B virus (HBV) cirrhosis patients is poorly defined. We assess the effect of DM on the HBV cirrhosis outcomes and survival.
METHODS: A retrospective study of HBV cirrhosis patients who sought care at a sole public hospital in a geographically defined region, from year 2000 to 2012. Cirrhosis complications, liver transplantations, and mortality were reviewed. Primary outcome is the composite of liver-related and overall mortality or orthotopic liver transplantation (OLT).
RESULTS: Two hundred twenty-three patients entered into the final analysis; 50 patients (22.4%) have DM at cirrhosis diagnosis. Seventy-two percent of DM patients have DM for more than 5 years at cirrhosis diagnosis. The incidence of hepatocellular carcinoma (HCC) was 25.4 and 60.5 per 1000 patient-years for non-DM and DM patients, respectively (P = 0.006). In multivariate analysis, DM was a predictor of HCC (hazard ratio [HR] 2.36, [1.14-4.85], P = 0.02), hepatic complications (HR 2.04, [1.16-3.59], P = 0.01), liver mortality or OLT (HR 2.26, [1.05-4.86], P = 0.04), and overall mortality or OLT (HR 2.25, [1.96-4.22], P = 0.01). Insulin and/or sulphonylurea use and poor diabetic control (glycosylated hemoglobin ≥ 7.0%) were predictors of HCC and cirrhosis complications (all P < 0.05). The 5-year liver-related mortality or OLT rate was 23.4% for DM patients and 9.4% for non-DM patients, respectively (P = 0.009).
CONCLUSION: The presence of DM and poor diabetic control at cirrhosis diagnosis significantly increase the rate of cirrhosis complications and reduced survival in patients with HBV cirrhosis. Improving diabetic control should be essential part of the cirrhosis care in these patients.
© 2014 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  chronic hepatitis B; cirrhosis; cirrhosis complications; hepatocellular carcinoma; insulin; liver-related mortality; sulphonylurea; type 2 diabetes mellitus

Mesh:

Year:  2015        PMID: 25250942     DOI: 10.1111/jgh.12790

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  27 in total

Review 1.  Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy.

Authors:  Diego García-Compeán; José Alberto González-González; Fernando Javier Lavalle-González; Emmanuel Irineo González-Moreno; Jesús Zacarías Villarreal-Pérez; Héctor J Maldonado-Garza
Journal:  Dig Dis Sci       Date:  2016-02       Impact factor: 3.199

2.  Integrated computational approaches to screen gene expression data to determine key genes and therapeutic targets for type-2 diabetes mellitus.

Authors:  Fahad A Alhumaydhi
Journal:  Saudi J Biol Sci       Date:  2022-02-10       Impact factor: 4.052

3.  Association between diabetes mellitus and cirrhosis mortality: the Singapore Chinese Health Study.

Authors:  George Boon-Bee Goh; An Pan; Wan-Cheng Chow; Jian-Min Yuan; Woon-Puay Koh
Journal:  Liver Int       Date:  2016-09-16       Impact factor: 5.828

4.  Infrared spectroscopic imaging detects chemical modifications in liver fibrosis due to diabetes and disease.

Authors:  Hari Sreedhar; Vishal K Varma; Francesca V Gambacorta; Grace Guzman; Michael J Walsh
Journal:  Biomed Opt Express       Date:  2016-05-27       Impact factor: 3.732

5.  Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: A meta-analysis.

Authors:  Ashwini Arvind; Zoe N Memel; Lisa L Philpotts; Hui Zheng; Kathleen E Corey; Tracey G Simon
Journal:  Metabolism       Date:  2021-04-21       Impact factor: 13.934

6.  Identifying patients with chronic hepatitis B at high risk of type 2 diabetes mellitus: a cross-sectional study with pair-matched controls.

Authors:  Yi Shen; Jian Zhang; Hui Cai; Jian-Guo Shao; You-Yi Zhang; Yan-Mei Liu; Gang Qin; Yan Qin
Journal:  BMC Gastroenterol       Date:  2015-03-19       Impact factor: 3.067

7.  The Application of Liver Stiffness Measurement in Residents Without Overt Liver Diseases Through a Community-Based Screening Program.

Authors:  Pin-Nan Cheng; Yen-Cheng Chiu; Hung-Chih Chiu; Shih-Chieh Chien
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

8.  Liver cirrhosis leads to poorer survival in patients with end-stage renal disease.

Authors:  Ae Jin Kim; Hye Jin Lim; Han Ro; Ji Yong Jung; Hyun Hee Lee; Wookyung Chung; Jae Hyun Chang
Journal:  Korean J Intern Med       Date:  2016-03-26       Impact factor: 2.884

9.  Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis?

Authors:  Fu-Shun Yen; Jung-Nien Lai; James Cheng-Chung Wei; Lu-Ting Chiu; Chih-Cheng Hsu; Ming-Chih Hou; Chii-Min Hwu
Journal:  BMC Gastroenterol       Date:  2021-06-12       Impact factor: 3.067

10.  Relationship between 25-Hydroxyvitamin D Levels and Liver Fibrosis as Assessed by Transient Elastography in Patients with Chronic Liver Disease.

Authors:  Bong Jin Ko; Young Seok Kim; Sang Gyune Kim; Jung Hwan Park; Sae Hwan Lee; Soung Won Jeong; Jae Young Jang; Hong Soo Kim; Boo Sung Kim; Sun Mi Kim; Young Don Kim; Gab Jin Cheon; Bo Ra Lee
Journal:  Gut Liver       Date:  2016-09-15       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.